Table 5. Most common grade 3–4 adverse events occurring in more than 5% of patients in the safety population.

	mFOLFIRINOX grade 3–4, n (%)	GEMOX grade 3–4, n (%)	P value
Event	12 (48.0)	7 (36.8)	0.459
Hematological
Neutropenia	7 (28.0)	3 (15.8)
Thrombocytopenia	2 (8.0)	4 (21.1)
Anemia	3 (12.0)	2 (10.5)
Non-hematological
Nausea	2 (8.0)	1 (5.3)
Vomiting	2 (8.0)	2 (10.5)
Anorexia	1 (4.0)	1 (5.3)
Diarrhea	4 (16.0)	1 (5.3)
Fatigue	3 (12.0)	2 (10.5)
Peripheral Neuropathy	2 (8.0)	4 (21.1)